Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Communication | 7 | 2023 | 608 | 1.850 |
Why?
|
| Internet | 6 | 2020 | 472 | 1.550 |
Why?
|
| Physician-Patient Relations | 6 | 2023 | 430 | 1.400 |
Why?
|
| Text Messaging | 2 | 2023 | 98 | 1.340 |
Why?
|
| Electronic Mail | 3 | 2020 | 46 | 1.130 |
Why?
|
| Physicians | 4 | 2019 | 488 | 0.990 |
Why?
|
| Blogging | 2 | 2017 | 11 | 0.940 |
Why?
|
| Hospitalists | 1 | 2023 | 37 | 0.760 |
Why?
|
| Medical Informatics | 2 | 2020 | 72 | 0.740 |
Why?
|
| Patient Portals | 2 | 2019 | 53 | 0.700 |
Why?
|
| Transgender Persons | 1 | 2022 | 68 | 0.660 |
Why?
|
| Patient Participation | 2 | 2019 | 239 | 0.570 |
Why?
|
| Cell Phone Use | 1 | 2018 | 1 | 0.550 |
Why?
|
| Consumer Health Informatics | 1 | 2017 | 1 | 0.520 |
Why?
|
| Video Recording | 1 | 2017 | 140 | 0.490 |
Why?
|
| Social Media | 2 | 2019 | 129 | 0.490 |
Why?
|
| Cystic Fibrosis | 1 | 2017 | 126 | 0.470 |
Why?
|
| Attitude of Health Personnel | 2 | 2022 | 634 | 0.460 |
Why?
|
| Pharmacies | 1 | 2016 | 36 | 0.460 |
Why?
|
| Health Behavior | 2 | 2018 | 485 | 0.440 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 741 | 0.420 |
Why?
|
| Consumer Health Information | 1 | 2014 | 41 | 0.420 |
Why?
|
| Value-Based Purchasing | 1 | 2013 | 8 | 0.390 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 489 | 0.390 |
Why?
|
| Costs and Cost Analysis | 1 | 2012 | 106 | 0.360 |
Why?
|
| Prescription Drugs | 1 | 2012 | 49 | 0.360 |
Why?
|
| Humans | 29 | 2025 | 65845 | 0.340 |
Why?
|
| Adult | 12 | 2023 | 17579 | 0.330 |
Why?
|
| Surveys and Questionnaires | 4 | 2019 | 2790 | 0.320 |
Why?
|
| Primary Health Care | 1 | 2016 | 726 | 0.310 |
Why?
|
| Drug Monitoring | 4 | 2013 | 203 | 0.310 |
Why?
|
| Quality Improvement | 1 | 2013 | 473 | 0.280 |
Why?
|
| Male | 15 | 2023 | 31410 | 0.270 |
Why?
|
| Hospitals | 2 | 2022 | 399 | 0.270 |
Why?
|
| Female | 15 | 2023 | 34425 | 0.260 |
Why?
|
| Drug Costs | 3 | 2013 | 55 | 0.250 |
Why?
|
| Early Detection of Cancer | 2 | 2021 | 327 | 0.250 |
Why?
|
| United States | 9 | 2019 | 8189 | 0.230 |
Why?
|
| Consent Forms | 1 | 2025 | 14 | 0.220 |
Why?
|
| Qualitative Research | 2 | 2022 | 763 | 0.220 |
Why?
|
| Informed Consent | 1 | 2025 | 142 | 0.200 |
Why?
|
| Insurance Coverage | 3 | 2013 | 98 | 0.200 |
Why?
|
| Indiana | 2 | 2020 | 21 | 0.200 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 2739 | 0.190 |
Why?
|
| Fasting | 1 | 2022 | 52 | 0.180 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 558 | 0.180 |
Why?
|
| Hypoglycemia | 1 | 2022 | 64 | 0.180 |
Why?
|
| Wearable Electronic Devices | 1 | 2022 | 79 | 0.170 |
Why?
|
| Drugs, Generic | 2 | 2012 | 20 | 0.170 |
Why?
|
| Gender Identity | 1 | 2022 | 69 | 0.170 |
Why?
|
| Drug Utilization | 2 | 2012 | 204 | 0.160 |
Why?
|
| Emotions | 1 | 2023 | 236 | 0.160 |
Why?
|
| Insurance, Pharmaceutical Services | 2 | 2011 | 17 | 0.160 |
Why?
|
| Mobile Applications | 1 | 2022 | 142 | 0.160 |
Why?
|
| Focus Groups | 1 | 2022 | 329 | 0.160 |
Why?
|
| Middle Aged | 11 | 2022 | 18501 | 0.160 |
Why?
|
| Information Seeking Behavior | 1 | 2020 | 39 | 0.160 |
Why?
|
| Professionalism | 1 | 2019 | 11 | 0.150 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 155 | 0.150 |
Why?
|
| Uncompensated Care | 2 | 2009 | 5 | 0.150 |
Why?
|
| Medical Assistance | 2 | 2009 | 10 | 0.150 |
Why?
|
| Financing, Organized | 2 | 2009 | 16 | 0.150 |
Why?
|
| Inventions | 1 | 2019 | 4 | 0.150 |
Why?
|
| Attitude | 1 | 2019 | 102 | 0.150 |
Why?
|
| Trust | 1 | 2019 | 82 | 0.140 |
Why?
|
| Aged | 9 | 2022 | 15147 | 0.140 |
Why?
|
| Young Adult | 5 | 2022 | 4883 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 290 | 0.140 |
Why?
|
| Adolescent | 5 | 2022 | 6368 | 0.130 |
Why?
|
| Urban Population | 1 | 2019 | 201 | 0.130 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2018 | 62 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 439 | 0.130 |
Why?
|
| Health Personnel | 1 | 2022 | 391 | 0.130 |
Why?
|
| Myocardial Infarction | 3 | 2013 | 922 | 0.130 |
Why?
|
| Personality Disorders | 1 | 2017 | 20 | 0.130 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2013 | 214 | 0.130 |
Why?
|
| Personality | 1 | 2017 | 29 | 0.130 |
Why?
|
| Rural Population | 1 | 2019 | 225 | 0.120 |
Why?
|
| Cost Sharing | 2 | 2013 | 15 | 0.120 |
Why?
|
| Disclosure | 3 | 2011 | 57 | 0.120 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 806 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2019 | 398 | 0.120 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2013 | 140 | 0.120 |
Why?
|
| Health Care Reform | 2 | 2013 | 86 | 0.110 |
Why?
|
| Anxiety Disorders | 1 | 2017 | 201 | 0.110 |
Why?
|
| Medicare | 1 | 2019 | 629 | 0.110 |
Why?
|
| Health Expenditures | 2 | 2013 | 122 | 0.110 |
Why?
|
| Cardiovascular Diseases | 2 | 2012 | 878 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2017 | 745 | 0.100 |
Why?
|
| Interviews as Topic | 1 | 2016 | 535 | 0.100 |
Why?
|
| Anxiety | 1 | 2017 | 427 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 413 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 770 | 0.100 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2013 | 63 | 0.100 |
Why?
|
| Data Collection | 1 | 2014 | 384 | 0.100 |
Why?
|
| Cost Savings | 1 | 2013 | 60 | 0.090 |
Why?
|
| Cost Control | 1 | 2012 | 24 | 0.090 |
Why?
|
| Telemedicine | 1 | 2018 | 379 | 0.090 |
Why?
|
| Drug Industry | 2 | 2009 | 41 | 0.090 |
Why?
|
| Medication Adherence | 1 | 2013 | 202 | 0.090 |
Why?
|
| Publications | 1 | 2011 | 29 | 0.080 |
Why?
|
| Conflict of Interest | 1 | 2011 | 38 | 0.080 |
Why?
|
| Developing Countries | 1 | 2011 | 87 | 0.080 |
Why?
|
| Health Resources | 1 | 2011 | 92 | 0.080 |
Why?
|
| Medical Oncology | 1 | 2011 | 70 | 0.080 |
Why?
|
| Cardiovascular Agents | 1 | 2011 | 107 | 0.080 |
Why?
|
| Depression | 1 | 2017 | 910 | 0.080 |
Why?
|
| Quality of Life | 1 | 2017 | 1266 | 0.080 |
Why?
|
| Voluntary Health Agencies | 1 | 2009 | 4 | 0.070 |
Why?
|
| Anticonvulsants | 1 | 2010 | 104 | 0.070 |
Why?
|
| Financing, Government | 1 | 2009 | 31 | 0.070 |
Why?
|
| Seizures | 1 | 2010 | 141 | 0.070 |
Why?
|
| Psychotropic Drugs | 1 | 2009 | 81 | 0.070 |
Why?
|
| Neoplasms | 1 | 2018 | 1378 | 0.070 |
Why?
|
| Drug Prescriptions | 1 | 2009 | 165 | 0.070 |
Why?
|
| Hypoglycemic Agents | 1 | 2009 | 226 | 0.060 |
Why?
|
| Health Services Accessibility | 2 | 2009 | 603 | 0.060 |
Why?
|
| Comprehension | 1 | 2025 | 143 | 0.050 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2022 | 62 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2025 | 462 | 0.040 |
Why?
|
| Outpatients | 1 | 2022 | 143 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2009 | 827 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2022 | 5682 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2021 | 97 | 0.040 |
Why?
|
| Overweight | 1 | 2022 | 254 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2013 | 462 | 0.040 |
Why?
|
| Weight Loss | 1 | 2022 | 276 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2022 | 502 | 0.040 |
Why?
|
| Alcoholic Intoxication | 1 | 2019 | 27 | 0.040 |
Why?
|
| Glucose | 1 | 2022 | 478 | 0.040 |
Why?
|
| Beneficence | 2 | 2009 | 4 | 0.040 |
Why?
|
| Evidence-Based Medicine | 2 | 2012 | 464 | 0.040 |
Why?
|
| Help-Seeking Behavior | 1 | 2019 | 10 | 0.040 |
Why?
|
| Culture | 1 | 2018 | 82 | 0.030 |
Why?
|
| Racism | 1 | 2019 | 93 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2009 | 318 | 0.030 |
Why?
|
| Neuroticism | 1 | 2017 | 3 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2017 | 278 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 448 | 0.030 |
Why?
|
| Obesity | 1 | 2022 | 1281 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 1793 | 0.030 |
Why?
|
| Myocardial Revascularization | 1 | 2013 | 78 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 2500 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2013 | 165 | 0.020 |
Why?
|
| Ticlopidine | 1 | 2012 | 47 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2012 | 56 | 0.020 |
Why?
|
| Deductibles and Coinsurance | 1 | 2011 | 9 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 375 | 0.020 |
Why?
|
| Retreatment | 1 | 2011 | 43 | 0.020 |
Why?
|
| Journal Impact Factor | 1 | 2011 | 26 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2012 | 153 | 0.020 |
Why?
|
| Authorship | 1 | 2011 | 26 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2013 | 310 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2011 | 152 | 0.020 |
Why?
|
| Editorial Policies | 1 | 2011 | 54 | 0.020 |
Why?
|
| Cardiology | 1 | 2012 | 172 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2012 | 235 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2012 | 224 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2012 | 5834 | 0.020 |
Why?
|
| Therapeutic Equivalency | 1 | 2010 | 16 | 0.020 |
Why?
|
| Altruism | 1 | 2009 | 14 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1148 | 0.020 |
Why?
|
| Financing, Personal | 1 | 2009 | 23 | 0.020 |
Why?
|
| Eligibility Determination | 1 | 2009 | 37 | 0.020 |
Why?
|
| Insurance Claim Review | 1 | 2009 | 76 | 0.020 |
Why?
|
| Government Regulation | 1 | 2009 | 39 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 5475 | 0.020 |
Why?
|
| Income | 1 | 2009 | 169 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 757 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 811 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2010 | 2116 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2009 | 2651 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2009 | 6957 | 0.010 |
Why?
|